| P50 | author | Natasha Vitkin | Q88751188 |
| P2093 | author name string | Andrew Robinson | |
| | Kasra Khalaj | |
| | Nichole Peterson | |
| | Madhuri Koti | |
| | Abdi Ghaffari | |
| | Julie-Ann Francis | |
| P2860 | cites work | Tumor-intrinsic oncogene pathways mediating immune avoidance | Q26747707 |
| | Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer | Q26780387 |
| | STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity | Q28509328 |
| | Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites | Q33748623 |
| | IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance | Q34512092 |
| | Unabated adenovirus replication following activation of the cGAS/STING-dependent antiviral response in human cells | Q34594959 |
| | Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. | Q50874203 |
| | Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy. | Q53033027 |
| | Direct activation of STING in the tumor microenvironment with synthetic cyclic dinucleotide derivatives leads to potent and systemic tumor-specific immunity | Q59400485 |
| | Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer | Q35044404 |
| | A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. | Q35274995 |
| | Combinatorial strategies for the induction of immunogenic cell death | Q35535140 |
| | Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity | Q35634752 |
| | STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade | Q35858368 |
| | Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy | Q35938555 |
| | Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma | Q36051184 |
| | STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation | Q36917725 |
| | STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. | Q37456596 |
| | STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. | Q37502349 |
| | Pharmacology and therapeutic potential of interferons | Q38000963 |
| | CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer | Q38711571 |
| | Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer | Q38715458 |
| | Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes | Q38747875 |
| | CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma | Q38751550 |
| | Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling | Q38801971 |
| | Systemic Immunity Is Required for Effective Cancer Immunotherapy | Q39006805 |
| | A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer | Q39263789 |
| | STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia | Q39708605 |
| | Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. | Q41346867 |
| | Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses | Q41770853 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | ovarian cancer | Q172341 |
| | carboplatin | Q415588 |
| | bites and stings | Q54911704 |
| P304 | page(s) | 440-449 | |
| P577 | publication date | 2018-07-26 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer | |
| P478 | volume | 119 | |